申请人:LI PENG
公开号:US20100273753A1
公开(公告)日:2010-10-28
1- or 2- or 7-(substituted)-3-(optionally hetero)arylamino-[1H, 2H]-pyrazolo[3,4-d] pyrimidine-4,6(5H, 7H)-dione derivatives, in free, salt or prodrug form, are useful as pharmaceuticals, particularly as phosphodiesterase 1 inhibitors, useful treatment of diseases involving disorders of the dopamine D1 receptor intracellular pathway, such as Parkinson's disease, depression, narcolepsy and damage to cognitive function, e.g., in schizophrenia or disorders that may be ameliorated through enhanced progesterone-signaling pathway, e.g., female sexual dysfunction.
1-或2-或7-(取代)-3-(可选杂原子)芳基氨基-[1H, 2H]-吡唑并[3,4-d]嘧啶-4,6(5H, 7H)-二酮衍生物,以自由、盐或前药形式使用作为药物,特别是作为磷酸二酯酶1抑制剂,有用于治疗涉及多巴胺D1受体细胞内通路紊乱的疾病,例如帕金森病、抑郁症、嗜睡症和损伤认知功能,例如在精神分裂症或可能通过增强孕激素信号通路改善的障碍,例如女性性功能障碍。